NCT01757132

Brief Summary

The objective of the PAS-01 study is to assess the safety of the intraocular as measured by the cumulative incidence of patients who within 5 years after implantation experience persistent vision-impairing corneal edema (corneal edema leading to persistent loss of best corrected distance visual acuity \>2 lines from pre-surgery baseline level). The study will test the null hypothesis that the percentage of patients who experience persistent vision-impairing corneal edema is \>17% against the alternative that the percentage is \<17%. The null hypothesis will be rejected if the upper bound of the two-sided 95% confidence integral for the observed percentage is \<17%.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
770

participants targeted

Target at P75+ for not_applicable

Timeline
31mo left

Started Aug 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

16 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Aug 2010Dec 2028

Study Start

First participant enrolled

August 1, 2010

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

November 13, 2012

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 28, 2012

Completed
10.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Expected
Last Updated

November 16, 2018

Status Verified

November 1, 2018

Enrollment Period

13.3 years

First QC Date

November 13, 2012

Last Update Submit

November 15, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Long term safety study of implantable miniature telescope

    Number of persistent vision impairing corneal edema adverse events

    5 years after implantation

Study Arms (1)

Implantable Miniature Telescope

OTHER

Post approval study

Device: Implantable Miniature Telescope

Interventions

Device - Implantable Miniature Telescope

Implantable Miniature Telescope

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • stable severe (BVDCA of 10/160 or poorer) to profound (BCDVA of 20/800 or better) vision impairment caused by bilateral central scotomas associated with end-stage age-related macular degeneration.
  • years of age or older
  • retinal findings of geographic atrophy or disciform scar with foveal involvement
  • visually significant cataract
  • agree to undergo pre- and post-surgery training and assessment
  • achieve at least a 5-letter improvement with external telescope
  • have adequate peripheral vision in the eye not scheduled for surgery

You may not qualify if:

  • Stargardt's macular dystrophy
  • Anterior chamber depth \< 3.0mm
  • Presence of corneal guttate
  • Do not meet minimum age and endothelial cell density requirements
  • evidence of CNV or treatment of CNV within the past 6 months
  • cognitive impairment that would interfere with ability to understand and complete Acceptance of Risk and Informed Decision Agreement or prevent proper training/rehabilitation
  • previous intraocular or cornea surgery of any kind in operative eye, including any type of surgery for either refractive or therapeutic purposes or who have prior or expected ophthalmic related surgery within 30 days preceding intraocular telescope surgery
  • history of steroid-responsive rise in intraocular pressure, uncontrolled glaucoma, or preoperative IOP \>22 mm Hg while on maximum medication
  • known sensitivity to post-operative medications
  • history of eye rubbing or an ocular condition that predisposes eye rubbing
  • myopia \>6.0 D
  • hyperopia \>4.0D
  • axial length \<21mm
  • narrow angle, i.e., \<Schaffer grade 2
  • cornea stromal or endothelian dystrophies, including guttate
  • +9 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (16)

Arizona Eye Center

Chandler, Arizona, 85225, United States

Location

Retinal Consultants of Arizona, LTD

Phoenix, Arizona, 85014, United States

Location

Barnet, Dulaney, Perkins Eye

Phoenix, Arizona, 85016, United States

Location

Retina-Vitreous Associates

Beverly Hills, California, 90211, United States

Location

Retina Consultants of Orange County

Fullerton, California, 92835, United States

Location

Loma Linda University Health Care

Loma Linda, California, 92350, United States

Location

University of California - Davis

Sacramento, California, 95817, United States

Location

Specialty Eye Care (Glaucoma Consultants of Colorado)

Parker, Colorado, 80134, United States

Location

Retina Speciality Institute

Pensacola, Florida, 32503, United States

Location

Sarasota Retinal Institute

Sarasota, Florida, 34239, United States

Location

Emory Eye Center

Atlanta, Georgia, 30322, United States

Location

University of Michigan, Kellogg Eye Center

Ann Arbor, Michigan, 48105, United States

Location

Pepose Vision Institute

Chesterfield, Missouri, 63017, United States

Location

New York Eye & Ear

New York, New York, 10003, United States

Location

Fine, Hoffman & Packer

Eugene, Oregon, 97401, United States

Location

Valley Retina Institute

McAllen, Texas, 78503, United States

Location

Study Officials

  • Oliver D Schein, MD

    Johns Hopkins University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 13, 2012

First Posted

December 28, 2012

Study Start

August 1, 2010

Primary Completion

December 1, 2023

Study Completion (Estimated)

December 1, 2028

Last Updated

November 16, 2018

Record last verified: 2018-11

Locations